CD274 and neoplasm: These nanocarriers bind to the PD-L1 expressed on tumor cells and block immune checkpoints, reactivating T cells, and at the same time, the RSL3 triggers ferroptosis cell death, leading to the release of tumor antigens and enhancing the immunogenicity.